PRAX
Praxis Precision Medicines, Inc.
NASDAQ · USHealthcareBiotechnology
$304.43-3.17%
Price as of Jul 20, 2026
PRAX financials
Praxis Precision Medicines, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $8.6M | $2.4M | $0.00 |
| Cost of revenue | $140.0K | $152.4M | $86.8M | $154.4M |
| Gross profit | -$140.0K | -$143.9M | -$84.3M | -$154.4M |
| Operating expenses | $326.1M | $56.3M | $42.1M | $60.5M |
| Operating income | -$326.2M | -$200.2M | -$126.4M | -$215.0M |
| Net income | -$303.3M | -$182.8M | -$123.3M | -$214.0M |
| EBITDA | -$303.1M | -$182.5M | -$122.8M | -$213.6M |
| Basic EPS | $-13.48 | $-10.21 | $-18.69 | $-69.33 |
| Diluted EPS | $-13.48 | $-10.21 | $-18.69 | $-69.33 |
| Balance sheet | ||||
| Cash & equivalents | $357.3M | $215.4M | $81.3M | $61.6M |
| Total assets | $937.9M | $483.1M | $87.9M | $115.1M |
| Total liabilities | $59.8M | $37.7M | $18.3M | $39.0M |
| Stockholders’ equity | $878.1M | $445.4M | $69.7M | $76.1M |
| Total debt | $110.0K | $1.4M | $2.5M | $3.5M |
| Net debt | -$357.2M | -$214.0M | -$78.8M | -$58.1M |
| Cash flow | ||||
| Operating cash flow | -$249.1M | -$131.8M | -$111.1M | -$185.0M |
| Capital expenditure | -$56.0K | $0.00 | -$50.0K | -$444.0K |
| Free cash flow | -$249.1M | -$131.8M | -$111.2M | -$185.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |